Ticlopidine

References

• Panak EA, Maffrand JP, Picard-Fraire C, Vallée E, et al. Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983;13(suppl 1):1-54.
   Google Scholar
• Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994;26:347–55.
   PubMed Web of Science ®Google Scholar
• Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents and Actions Suppl 1984;15:68–75.
   Google Scholar
• Teitelbaum P, Gabuzda TG, Koretz SH, Massey I, et al. Pharmacokinetics of ticlopidine in young and old adult subjects following single and multiple dosing (abstract). J Pharmaceut Sci 1987;76:599.
   Google Scholar
• Shah J, Teitelbaum P, Molony BA, Gabuzda T, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Pharmacol 1991;32:761–4.
   Google Scholar
• Knudsen JB, Bastain W, Sefton CM, Allen JG, et al. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992;22:579–89.
   PubMed Web of Science ®Google Scholar
• Shah J, Fratis A, Ellis D, Marukami S, et al. Effect of food and antacid on absorption of orally administered ticlipi-dine hydrochloride. J Clin Pharmacol 1990;30:733–6.
   PubMed Web of Science ®Google Scholar
• Picard-Fraire C. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration, and effect on platelet function. Thromb Res 1983;Suppl IV:119-28.
   Google Scholar
• Savi P, Combalbert J, Gaich C, Rouchon MC, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313–7.
   PubMed Web of Science ®Google Scholar
• Desager, JP, van Nieuwenhuyze Y, Dricot J, Berger Y, et al. Pharmacokinetic profile and bioavailability of a new galenic formulation of ticlopidine. Int J Clin Pharmacol 1990;10(4):247–50.
   Google Scholar
• Teitelbaum P. Pharmacodynamic and pharmacokinetics of ticlopidine. In: Haas WK, Easton JD, eds. Ticlopidine, Platelets, and Vascular Disease. Springer-Verlag, New York: 1993:27–40.
   Google Scholar
• Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987;34:222–62.
   Google Scholar
• Tuong A, Bouyssou A, Paret J, Cuong TG. Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile. Eur J Drug Metab Pharmacokinet 1981;6:91–8.
   PubMedGoogle Scholar
• Syntex Laboratories Inc. Ticlid1 (Ticlopidine Hydrochloride) Tablets Prescribing Information. California, USA: Palo Alto, 1995.
   Google Scholar
• Buur T, Larsson R, Berglund U, Donat F, et al. Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharmacol 1997;37:108–15.
   PubMed Web of Science ®Google Scholar
• Gidal BE, Sorkness CA, McGill KA, Larson R, et al. Evaluation of a potential enantioselective interaction between ticlopidione and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995;17:33–8.
   Google Scholar
• Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. Effect of ticlopidine treatment on liver metaboliziing enzymes in man. Br J Clin Pharmacol 1980;10:311–3.
   Google Scholar
• Colli A, Buccino G, Cocciolo M, Parravicini E, et al. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987;41:358–62.
   Google Scholar
• Brown RI, Cooper TG. Ticlopidine-carbamazepine interaction in a coronary stent patient. Can J Cardiol 1997; 13:853–4.
   Google Scholar
• Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacother 1997;62:572–7.
   Google Scholar
• Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother 1998;32:1295–8.
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. A possible method to control prolongations of bleeding time under antiplatelet therapy with ticlopidine. Thromb Haemost 1982;48:6–8.
   Google Scholar
• Birmelé B, Lebranchu Y, Bagros P, Nivet H, et al. Interaction of cyclosporin and ticlopidine. Nephrol Dial Transplant 1991;6:150–1.
   Google Scholar
• Verdejo A, de Cos MA, Zubimendi JA. Probable interaction between cyclosporin A and low dose ticlopi-dine. BMJ 2000;320:1037.
   Google Scholar
• Feriozzi S, Massimetti C, Ancarani E. Treatment with ticlopidine is associated with reduction of cyclosporin A blood levels. Nephron 2002;92:249–50.
   Web of Science ®Google Scholar
• Vargas R, Reitman M, Teitelbaum P, Ryan JR, et al. Study of the effect of ticlopidine on digoxin blood levels (Abstract). Clin Pharmacol Ther 1988;43:176.
   Google Scholar
• Spaulding C, Charbonnier B, Cohen-Solal A, Juilliere Y, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: Results of double-blind, randomized comparative trial. Circulation 1998;98:757–65.
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. The interactions of ticlopidine and aspirin in normal subjects. J Int Med Res 1977;5:405–11.
   PubMedGoogle Scholar
• Uchiyama S, Sone R, Nagayama T, Shibagaki Y, et al. Combination therapy with low-dose aspirin and ticlopi-dine in cerebral ischemia. Stroke 1989;20:1643–7.
   PubMed Web of Science ®Google Scholar
• Cadroy Y, Bossavy J-P, Thalamus C, Sagnard L, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823–8.
   PubMed Web of Science ®Google Scholar
• Bossavy J-P, Thalamus C, Sagnard L, Barret A, et al. A double-blind randomised comparison of combined aspirin and ticlopidine versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998;92:1518–25.
   PubMed Web of Science ®Google Scholar
• Herbert JM, Bernat A, Samama M, Maffrand JP. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in rat. Thromb Haemost 1996;76:94–8.
   PubMed Web of Science ®Google Scholar
• Umemura K, Knodo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997;78:1381–4.
   Web of Science ®Google Scholar
• Peter K, Kohler B, Straub A, Ruef J, et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: Continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000;102:1490–6.
   PubMedGoogle Scholar
• Takase K, Fujioka H, Ogasawara M, et al. Drug-induced hepatitis during combination therapy of warfarin potassium and ticlopidine hydrochloride. Mie Med J 1990; 40:27–32.
   Google Scholar
• Ueno M, Masuda H, Nakamura K, Sakata R. Antiplatelet therapy for a pregnant woman with a mechanical aortic valve: report of a case. Surg Today 2001;31:1002–4.
   Google Scholar
• Sebastian C, Scherlag M, Kugelmass A, Schechter E. Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin. Cath Cardiovasc Diagn 1998;45:275–9.
   PubMedGoogle Scholar
• O'Brien M, Parness IA, Neureld EJ, Baker AL, et al. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. (Abstract) Pediatrics 2000;105:E64.
   Google Scholar
• Humberclaude V, Vallee L, Sukno S, Vamecq J, et al. Cerebral venous thrombosis disclosing Bechet disease. (Abstract) Arch Fr Pediatr 1993;50:603–5.
   Google Scholar
• Elf-Sanofi. TICLID1 (ticlopidine hydrochloride) Product Monograph. Gentilly, France: Sanofi Pharma, 1993.
   Google Scholar
• Molony BA. An analysis of the side effects of ticlopidine: In: Hass WK, Easton JD, eds. Ticlopidine, Platelets and Vascular Disease. New York: Springer-Verlag, 1993: 117–39.
   Google Scholar
• Roche Laboratories Inc. Ticlid1 (Ticlopidine Hydrochloride). Product Monograph. New Jersey, USA: Nutley, 1999–2001.
   Google Scholar
• Lecompte T. Antiplatelet agents and their therapeutic use. Rev Prat 1999;49:1627–33.
   Google Scholar
• Daniel JL, Dangelmaier C, Jin J, Ashby B, et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998;273:2024–9.
   Google Scholar
• Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 1998;351:235–46.
   PubMedGoogle Scholar
• Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization on the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591–8.
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D, Li G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202–7.
   PubMed Web of Science ®Google Scholar
• Defreyn G, Gachet C, Savi P, Driot F, et al. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991;65:186–90.
   PubMed Web of Science ®Google Scholar
• Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979;300:1142.
   PubMed Web of Science ®Google Scholar
• Ashida S-I, Abiko Y. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemost 1979;41:436–49.
   Google Scholar
• Geiger J, Brich J, Honig-Leidl P. Thienopyridine-based antiplatelet drugs inhibit ADP effects on prostaglandin-stimulated, cAMP/PKA-mediated phosphorylation of the cytoskeletol protein VASP in human platelets. (Abstract) Circulation 1998;98(Suppl I): I-595.
   Google Scholar
• Heptinstall S, May JA, Glenn JR, Sanderson HM, et al. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost 1995;74:1310–5.
   PubMed Web of Science ®Google Scholar
• Chignard M, Lalau Keraly C, Delautier D, Sebag C, et al. Reduced sensitivity of human platelets to PAF-acether following ticlopidine intake. Haemostasis 1989;19:213–8.
   Google Scholar
• Hanson SR, Harker LA. Baboon models of acute arterial thrombosis. Thromb Haemost 1987;58:801–5.
   Google Scholar
• Moliterno DJ, Topol EJ. Meta-analysis of platelet glycoprotein IIb/IIIa antagonist randomized clinical trials in ischemic heart disease: consistent, durable salutary effects. (Abstract) Circulation 1997;96(Suppl I): I-475.
   Google Scholar
• Conrad J, LeCrubier C, Scarabin PY, Horellow MH, et al. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980;20:143–8.
   Google Scholar
• van Gestel MA, Heemskerk JWM, Slaaf DW, Heijnen W, et al. In vivo Blockade of Platelet ADP Receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 2003; 23:518–23.
   PubMed Web of Science ®Google Scholar
• Di Minno G, Cerbone AM, Mattioli PL, Turco S, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328–38.
   PubMed Web of Science ®Google Scholar
• David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res 1979;14:35–49.
   Google Scholar
• Gryglewski RJ, Korbut R, Swies J, Kostka Trabka E, et al. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol 1996;308:61–7.
   Google Scholar
• Gryglewski RJ, Uracz W, Swies J. Unusual effects of aspirin on ticlopidine induced thrombolysis. Thorax 2000;55(Suppl 2):S17–S19.
   Google Scholar
• Gryglewski RJ, Dupin JP, Uracz W, Swies J, et al. Thrombolysis by thienopyridines and their congeners. J Physiol Pharmacol 2000;51:683–93.
   Google Scholar
• Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667–72.
   PubMed Web of Science ®Google Scholar
• Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129:394–405.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
   Google Scholar
• Balsano F, Rizzon P, Violi F, Scrutino D, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter trial: the Studio della Ticlopidina nell'Angina Tnstabile Group. Circulation 1990;82:17–26.
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD, Ellis DJ, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–20.
   PubMed Web of Science ®Google Scholar
• Arcan JC, Blanchard J, Biossel JP, Destor JH, et al. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988;39:802–11.
   PubMed Web of Science ®Google Scholar
• Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989;62:681–5.
   Google Scholar
• Janzon L, Bergqvist D, Boberg J, Boberg M, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990;227:301–8.
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995;10:69–76.
   PubMed Web of Science ®Google Scholar
• Blanchard J, Carreras LO, Kindermans M, EMATAP Group. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol 1993;35:523–8.
   Google Scholar
• Janzon L. The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study. Vasc Med 1996;1:141–3.
   Google Scholar
• Chevigne M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg 1984;37:371–8.
   PubMedGoogle Scholar
• Limet R, David JL, Magotteaux P, Larock MP, et al. Prevention of aorto-coronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773–83.
   PubMed Web of Science ®Google Scholar
• Becquemin J-P, for the Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997;337:1726–31.
   Google Scholar
• The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990;108:1577–83.
   Google Scholar
• Wysowski DK, Bacsanyi J. Blood dyscrasias and hemato-logic reactions in ticlopidine users [Letter]. JAMA 1996; 276:952.
   Google Scholar
• Molony BA. An analysis of the side effects of ticlopidine. In: Hass WK, Easton JD, eds. Ticlopidine, Platelets, and Vascular Disease. Springer-Verlag, New York: 1993: 117–39.
   Google Scholar
• Richardson G, Curzen NP, Preston MA, Mills PG. Failure to monitor ticlopidine: the case for clopidogrel. Int J Cardiovasc Intervent 2000;3:29–33.
   Google Scholar
• Love B, Biller J, Gent M. Adverse haematological effect of ticlopidine: prevention, recognition and management. Drug Safety 1998;19:89–98.
   PubMed Web of Science ®Google Scholar
• Ono K, Kurohara K, Yoshihara M, et al. Agranulocytosis caused by ticlopidine and its mechanism. Am J Haematol 1991;37:239–42.
   PubMed Web of Science ®Google Scholar
• Gill S, Majumdar S, Brown NE, Armstrong PW. Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. Can J Cardiol 1997;13:909–13.
   PubMed Web of Science ®Google Scholar
• Page Y, Tardy B, Zeni F, Comtet C, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337:774–6.
   PubMed Web of Science ®Google Scholar
• Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke 1992;23:922–3.
   Google Scholar
• Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993;27:1060–1.
   Google Scholar
• Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States: an analysis of rational mortality data, 1968-1991. Am J Haematol 1995;50:84–90.
   PubMed Web of Science ®Google Scholar
• Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis. [Letter] Am J Hematol 1997;54:175–6.
   Google Scholar
• Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. [Letter] N Engl J Med 1997;337: 1245.
   Google Scholar
• Steinhubl SR, Tan WA, Foody JM, Topol EJ, for the EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999;281:806–10.
   Google Scholar
• Turken O, Ozturk A, Orphan B, Kandemir G, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Acta Haematol 2003;109:40–2.
   Google Scholar
• Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, et al. Thrombotic thrombocytopenic purpura assoiated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541–4.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Kiss JE, Weinberg PD, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998; 352:1036–7.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary stents and stroke prevention. Arch Intern Med 1999;159:2524–8.
   PubMed Web of Science ®Google Scholar
• Tsai H-M, Rice L, Sarode R, Chow TW, et al. Antibody inhibitors to von Willebrand Factor Metalloproteinase and increased binding of von Willebrand Factor to platelets in Ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794–9.
   PubMed Web of Science ®Google Scholar
• Mansoor GA, Aziz K. Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy. Ann Pharmacother 1997;31:870–2.
   Google Scholar
• Brigot C, Courillon-Mallet A, Roucayrol AM, et al. Lymphocytic colitis and ticlopidine. [Letter] Gastroenterol Clin Biol 1998;22:361–2.
   Google Scholar
• Swine C, Cornelette P, Van Pee D, Delos M, et al. Ticlopidine, diarrhea and lymphocytic colitis. [Letter] Gastroenterol Clin Biol 1998;22:475–6.
   Google Scholar
• Fuste L, Arevalo D, Gomez M, Planas A, et al. Lymphocytic colitis during treatment with ticlopidine. Gastroenterol Hepatol 2000;23:363–4.
   Google Scholar
• Feurle GE, Bartz KO, Schmitt-Graff A. Lymphocytic colitis, induced by ticlopidine. Z Gastroenterol 1999;37:1105–8.
   PubMedGoogle Scholar
• Ruget O, Burtin P, Cerez H, Cales P, et al. Chronic diarrhea associated with villous atrophy and lymphocytic gastritis, caused by ticlopidine. [Letter] Gastroenterol Clin Biol 1992;16:290.
   Google Scholar
• Prost C, Veyre B, Ollivier L, Daurat MO, et al. Imputable cutaneous eruption caused by ticlopidine after implantation of a coronary endoprosthesis: why not continue treatment? Presse Med 2000;29:303–5.
   Google Scholar
• Whetsel TR, Bell DM. Rash in patients receiving ticlopidine after intracoronary stent placement. Pharmacotherapy 1999;19:228–31.
   Google Scholar
• Yosipovitch G, Rechavia E, Feinmesser M, David M. Adverse cutaneous reactions to ticlopidine in patients with coronary stents. J Am Acad Dermatol 1999;41:473–6.
   PubMed Web of Science ®Google Scholar
• Borras-Blasco J, Navarro-Ruiz A, Gutierrez-Casbas A, Matarredona-Catala J, et al. Multiple fixed-drug eruption and diarrhea with ticlopidine. Ann Pharmacother 2002;36:344–5.
   Google Scholar
• His DH, Mock DJ, Rocco Jr TA. Toxic erythroderma due to ticlopidine. N Engl J Med 1999;340:1212.
   Google Scholar
• Pintor E, Sanmartin M, Azcona L, Hernandez R, et al. Leukocytoclastic vasculitis associated with ticlopidine. (Abstract) Rev Esp Cardiol 2001;54:114–6.
   Google Scholar
• Takishita S, Kawazoe N, Yoshida T, Fukiyama K. Ticlopidine and thrombocytopenia. [Letter] N Engl J Med 1990;323:1487–8.
   Google Scholar
• Mataix R, Ojeda E, Perez MC, Jimenez S. Ticlopidine and severe aplastic anaemia. Br J Haematol 1992;80:125–6.
   Google Scholar
• Kao TW, Hung CC, Chen YC, Tien HF. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Hematol 1997;98:211–3.
   Google Scholar
• Yeh SP, Hsueh EJ, Wu H, Wang YC. Ticlopidine-associated aplastic anemia. A case report and review of literature. Ann Hematol 1998;76:87–90.
   Google Scholar
• Alba PM, Baez JM, Paz A, Monge M, et al. Atypical microangiopathy in a patient treated with ticlopidine. Haematologica 1998;83:380–1.
   Google Scholar
• Sossai P, Corte GD, Marenzi R. Liver injury with the use of ticlopidine. Ann Pharmacother 1998;32:1370–1.
   Google Scholar
• Pizarro AE, Andrade RJ, Garcia-Cortes M, Lucina MI, et al. Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature. (Abstract) Rev Neurol 2001; 33:1014–20.
   Google Scholar
• Chen LK, Hsieh BH, Chen WC, Tsai ST, et al. Ticlopidine-induced hepatitis. Zhonghua Yi Xue Za Zhi(taipei) 2001;64:59–63.
   PubMedGoogle Scholar
• Adams L, Jeffrey GP, Deboer B, Garas G. Ticlopidine-associated cholestatic hepatitis. Intern Med J 2002;32:359–60.
   PubMed Web of Science ®Google Scholar
• Rosen H, el-Hennawy AS, Greenberg S, Chen CK, et al. Acute interstitial nephritis associated with ticlopidine. Am J Kidney Dis 1995;25:934–6.
   Google Scholar
• Elsman P, Zijlstra F. Ticlopidine and renal function. (Letter) Lancet 1996;348:273–4.
   Google Scholar
• Virdee M, Collinson J, Stables RH. Ticlopidine and renal function. (Letter) Lancet 1996;348:1031–2.
   Google Scholar
• Persoz CF, Cornella F, Kaeser P, Rochat T. Ticlopidine-induced interstitial pulmonary disease. Chest 2001;119:1963–5.
   Google Scholar
• Alanzo-Martinez JL, Elejalde-Guerra JI, Larrinaga-Linero D. Bronchiolitis obliteran-organizing pneumonia caused by ticlopidine. (Letter) Ann Intern Med 1998;129:71–2.
   Google Scholar
• Oon PC, Jerng JS, Kao HL, Chang YL, et al. Diffuse alveolar damage associated with ticlopidine use: a case report. J Formos Med Assoc 2003;102:262–5.
   Google Scholar
• Dakik HA, Salti I, Haidar R, et al. Ticlopidine associated with acute arthritis. BMJ 2002;324:27.
   Google Scholar
• Spiera RF, Berman RS, Werner AJ, Spoera H. Ticlopi-dine-induced Lupus: A report of 4 cases. Arch Intern Med 2002;162:2240–3.
   Google Scholar
• Sadowski Z, Kuczak D, Dyduszynski A, et al. Comparison of ticlopidine and aspirin in unstable angina. (Abstract) Eur Heart J 1995;16(Suppl):259.
   Google Scholar
• Scrutinio D, Climminiello C, Marubini E, et al. Ticlopi-dine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001;37:1259–65.
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HP, et al., for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501–7.
   Google Scholar
• Tohgi H. The effect of Ticlopidine on TIA compared with Aspirin - A double-blind, twelve-month and open 24-month follow-up study. Jpn J Med 1987;26:117–9.
   Google Scholar
• Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease. Stroke 2000;31:1779–84.
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Richardson DJ, Kelly M, et al. for the African American Antiplatelet Stroke Prevention Study (AAAPS) Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients. A randomized trial. JAMA 2003;289:2947–57.
   Google Scholar
• CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1333–8.
   Google Scholar
• Bergamasco B, Benna P, Carolei A, et al., and the TISS group. A randomized trial comparing ticlopidine hydro-chloride with indobufen for the prevention of stroke in high-risk patients (TISS STUDY). Funct Neurol 1997; 12:33–43.
   Google Scholar
• Siegerstetter V, Huber M, Ochs A, Blum HE, et al. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment. Hepatology 1999;29:33–8.
   Google Scholar
• Cosmi B, Rubboli A, Castelvetri C, Milandri M. Ticlopidine versus oral anticoagulation for coronary stenting (Cochrane Review). In: The Cochrane Library, Issue 1. John Wiley & Sons Ltd, Chichester, UK: 2004.
   Google Scholar
• Schömig A, Neumann FJ, Kastrati A, Schuhlen H, et al.A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084–9.
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J, Fleck E, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998;98:1597–603.
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, Gordon PC, et al. A clinical trial comparing 3 antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998;339:1665–71.
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht H-J, Kiemeneij F, et al. for the MATTIS Investigators. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. Circulation 1998; 98:2126–32.
   Google Scholar
• Dörffier-Melly J, Buller HR, Koopman MM, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery (Cochrane Review). In: The Cochrane Library, Issue 1. John Wiley & Sons Ltd, Chichester, UK: 2004.
   Google Scholar
• Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, et al. Meta- Analysis of Randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9–14.
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624–9.
   Google Scholar
• Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001;104:539–43.
   PubMed Web of Science ®Google Scholar
• Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Circulation 2000;101:590–3.
   PubMed Web of Science ®Google Scholar
• Kamishirado H, Inoue T, Mizoguchi K, Uchida T, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 2002;144(2):303–8.
   Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.
   Google Scholar
• Steinhubl SR, Berger PB, Mann JT III, Fry ET, et al, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002;288:2411–20.
   Google Scholar
• The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
   Google Scholar
• Chen MS, Bhatt DL, American College of Cardiology; American Heart Association. Highlights of the 2002 update to the 2000 American College of Cardiology/ American Heart Association acute coronary syndrome guidelines. Cardiol Rev 2003;11:113–21.
   Google Scholar
• Bennett CL, Connors JM, Carwile JM, Hoake JL, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773–7.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Connors JM, Moake JL. Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med 2000;343:1191–4.
   Google Scholar
• Hankey GJ. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000;356:269–70.
   Google Scholar
• Moussa I, Oetgen M, Roubin G, Colombo A, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in prevention stent thrombosis after coronary stent implantation. Circulation 1999;99:2364–6.
   PubMed Web of Science ®Google Scholar
• Berger PB, Bell MR, Rihal CS, Ting H, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34:1891–4.
   PubMed Web of Science ®Google Scholar
• L'Allier PL, Aronow HD, Cura FA, Bhatt DL, et al. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. Can J Cardiol 2003;19:1041–6.
   Google Scholar